Journal of Neurology

, Volume 253, Supplement 4, pp iv36–iv38

Ergoline and non-ergoline derivatives in the treatment of Parkinson’s disease

  • Heinz Reichmann
  • Anja Bilsing
  • Reinhard Ehret
  • Wolfgang Greulich
  • Jörg B. Schulz
  • Andreas Schwartz
  • Olivier Rascol
WORKSHOP 3

Abstract

There are a large variety of dopamine agonists available. Especially de novo patients are treated with dopamine agonists to avoid dyskinesia. Dopamine agonists can be subdivided into ergoline and non-ergoline derivatives. This distinction raises the question whether there are differences in the effects to treat symptoms, not only in the side effects between the individual dopamine agonists but also between these two groups. Pergolide is now considered a second line drug because of its particularly high tendency towards valvular heart disease. Some authors claim that all ergoline-derivatives may cause this problem, while own results do not necessarily support this view. We recommend performing echocardiography on those patients being treated with an ergotderivative. New data support the view that all dopaminergic drugs may cause somnolence and that there is no preference for non-ergots. It may be that the number of gamblers is slightly higher among patients treated with pramipexole than in others. Dopamine agonists with a high affinity to D3 receptors have a good anti-anhedonic potency. In cell culture all dopamine agonists studied so far show neuroprotective properties in cell culture. The introduction of a slow-release formulation for ropinirole and the rotigotine and lisuride patches have opened new ways of continuous dopamine receptor stimulation. Taken together, dopamine agonists show individual properties and there are differences between ergot and non-ergot derivatives.

Key words

Parkinson’s disease dopamine agonists ergot non-ergot somnolence valvulopathy dyskinesia 

References

  1. 1.
    Baseman DG, O’Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey Jr. RB (2004) Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 63:301–304PubMedGoogle Scholar
  2. 2.
    Dhawan V,Medcalf P, Stegie F, Jackson G, Basu S, Luce P,Odin P, Chaudhuri KR (2005) Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson’s disease patients treated with cabergoline. J Neural Transm 112:661–668PubMedCrossRefGoogle Scholar
  3. 3.
    Eggert K, Odin P, Gasser T,Meinertz T, Strasser R, Osterspey A, Deuschl G, Oertel WH (2005) Fachgerechter Einsatz von Dopamin-Agonisten. Deutsches Ärzteblatt 102:B22–B23Google Scholar
  4. 4.
    Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JH, Abbaszade I, Hollis JM, Largent BI, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW (2000) Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57:75–81PubMedGoogle Scholar
  5. 5.
    Flowers CM, Racoosin JA, Lu SL, Beitz JG (2003) The US Food and Drug Administration’s registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 78:730–731PubMedGoogle Scholar
  6. 6.
    Frucht S, Rogers JD, Greene PE (1999) Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52:1908–1910PubMedGoogle Scholar
  7. 7.
    Hanna PA, Ratkos L, Ondo WG, Jankovic J (2001) Switching from pergolide to pramipexole in patients with Parkinson’s disease. J Neural Transm 108:63–70PubMedCrossRefGoogle Scholar
  8. 8.
    Horowski R, Jahnichen S, Pertz HH (2004) Fibrotic valvular heart disease is not related to chemical class but to biological function: 5-HT2B receptor activation plays crucial role. Mov Disord 19(12):1523–1524PubMedCrossRefGoogle Scholar
  9. 9.
    Horvath J, Fross RD, Kleiner-Fisman G, Lerech R, Stadler H, Liaudat S, Raskoff WJ, Flachsbart KD, Rakowski H, Pache JC, Burkhard PR, Lang AE (2004) Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 19:656–662PubMedCrossRefGoogle Scholar
  10. 10.
    Jahnichen S, Horowski R, Pertz HH (2005) Agonism at 5-HT2B receptors is not a class effect of the ergolines. Eur J Pharmacol 513:225–228PubMedCrossRefGoogle Scholar
  11. 11.
    Junghanns S, Fuhrmann JT, Simonis G, Oehlwein Ch, Koch R, Strasser RH, Reichmann H, Storch A (2006) Valvular heart disease in Parkinson’s disease treated with dopamine agonists: A reader-blinded monocenter echocardiography study. Mov Disord (in press)Google Scholar
  12. 12.
    Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. JAMA 287:1653–1661CrossRefGoogle Scholar
  13. 13.
    Parkinson Study Group (2004) Levodopa and the progression of Parkinson’s disease. New Engl J Med 351:2498–2508CrossRefGoogle Scholar
  14. 14.
    Peralta C, Wolf E, Alber H, et al. (2006) Valvular heart disease in Parkinson’s disease vs. controls: An echocardiographic study. Mov Disord; published onlineGoogle Scholar
  15. 15.
    Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE (2002) Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77:1280–1286PubMedCrossRefGoogle Scholar
  16. 16.
    Reichmann H, Brecht MH, Koster J, Kraus PH, Lemke MR (2003) Pramipexole in routine clinical practice: a prospective observational trial in Parkinson’s disease. CNS Drugs 17:965–973PubMedCrossRefGoogle Scholar
  17. 17.
    Serratrice J, Disdier P, Habib G, Viallet F, Weiller PJ (2002) Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev 10:334–336PubMedCrossRefGoogle Scholar
  18. 18.
    Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, De Sutter J, Santens P, Decoodt P, Moerman C, Schoors D (2004) Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet 363:1179–1183PubMedCrossRefGoogle Scholar
  19. 19.
    Waller EA, Kaplan J, Heckman MG (2005) Valvular heart disease in patients taking pergolide. Mayo Clin Proc 80:1016–1020PubMedGoogle Scholar
  20. 20.
    Whone AJ, Watts RL, Stoessl AJ, Brooks DJ (2003) Slower progression of Parkinson’s disease with ropinirole versus levo-dopa. Ann Neurol 54:93–101PubMedCrossRefGoogle Scholar
  21. 21.
    Yamamoto M, Uesugi T (2005) Cardiac valvulopathy in Parkinson’s disease. Mov Disord 20(Suppl 10):P317Google Scholar
  22. 22.
    Zadikoff C, Rochon P, Lang A (2006) Cardiac valvulopathy associated with pergolide use. Can J Neurol Sci 33:27–33PubMedGoogle Scholar

Copyright information

© Steinkopff-Verlag 2006

Authors and Affiliations

  • Heinz Reichmann
    • 1
    • 8
  • Anja Bilsing
    • 2
  • Reinhard Ehret
    • 3
  • Wolfgang Greulich
    • 4
  • Jörg B. Schulz
    • 5
  • Andreas Schwartz
    • 6
  • Olivier Rascol
    • 7
  1. 1.Dept. of NeurologyUniversity of DresdenDresdenGermany
  2. 2.Paracelsus Northsea ClinicHelgolandGermany
  3. 3.BerlinGermany
  4. 4.Dept. Neurology AmbrockUniversity Witten-HerdeckeHagenGermany
  5. 5.Dept. of Neurodegeneration & Restorative ResearchUniversity of GöttingenGöttingenGermany
  6. 6.Neurological ClinicNordstadt KrankenhausHannoverGermany
  7. 7.Dept. of Clinical PharmacologyFaculty of MedicineToulouseFrance
  8. 8.Klinik und Poliklinik für NeurologieUniversitätsklinikum Carl Gustav Carus Technische Universität DresdenDresdenGermany

Personalised recommendations